J Obes 2011:432607
Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago
To view a copy of this license, visit About this article Cite this article Scarpellini, E., Arts, J., Karamanolis, G
Please review the product package before consuming and do not rely only on the details shown here, especially but not limited to ingredients and allergens
In terms of where the evidence sits right now, semaglutide has the strongest cardiac safety profile because it has the most data
These drugs, such as semaglutide, liraglutide etc., mimic the effects of a natural hormone (GLP-1 hormone) produced by the body, such as reducing appetite, improving insulin activity and supporting metabolism 1